Organon LLC

Gynecology and Women’s Health

Organon LLC focuses on clinical research in gynecologic pain, with particular attention to endometriosis-related pain in adult women. The trial activity reflects interest in conditions that affect pelvic health and daily functioning.

  • Endometriosis
  • Pelvic pain
  • Women’s reproductive health

The sponsor’s research landscape is centered on therapeutic areas relevant to symptom relief and disease burden in reproductive medicine.

Pain Management

Clinical investigation includes overall pelvic pain associated with endometriosis, highlighting a therapeutic interest in chronic pain conditions that require targeted symptom control.

  • Chronic pelvic pain
  • Analgesic development
  • Symptom reduction

This area emphasizes outcomes related to pain intensity, patient-reported discomfort, and functional impact in women with endometriosis-related symptoms.

Reproductive Endocrinology

The sponsor’s trial portfolio includes conditions linked to hormone-sensitive disease and the management of gynecologic disorders that influence reproductive health.

  • Hormone-related disorders
  • Menstrual pain
  • Pelvic disorder management

Research interest in this domain aligns with treatment needs for women experiencing persistent pain tied to endometriosis.

Safety and Tolerability in Therapeutic Development

Organon LLC also places emphasis on the safety and tolerability of investigational therapies used for moderate to severe endometriosis-related pain, supporting clinical evaluation in a broad adult population.

  • Adult women aged 18 to 49
  • Treatment tolerability
  • Patient-reported outcomes

This area reflects ongoing interest in therapeutic options for women with persistent pelvic pain requiring medical intervention.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Hungary +4